Showing results (51-60 of 182) with videos related to
Sort By:
Pageof 19
Oncology (Williston Park, N.Y.)|August 1, 1987
Status and potential of interleukin-2 for the treatment of neoplastic diseaseP M Sondel, J A Hank, P C KohlerLipids|June 4, 2008
Fatty acid profile of sunshine bass: I. Profile change is affected by initial composition and differs among tissuesJesse T Trushenski, Heidi A Lewis, Christopher C KohlerJournal of Global Health|December 8, 2023
Shared health governance, mutual collective accountability, and transparency in COVAX: A qualitative study triangulating data from document sampling and key informant interviewsAriel Gorodensky, Quinn Grundy, Navindra Persaud, et al.Organic Letters|July 1, 2011
Catalytic asymmetric addition of thiols to nitrosoalkenes leading to chiral non-racemic α-sulfenyl ketonesJohn M Hatcher, Mark C Kohler, Don M ColtartGlobalization and Health|October 31, 2009
Transparency in Nigeria's public pharmaceutical sector: perceptions from policy makersHabibat A Garuba, Jillian C Kohler, Anna M HuismanEpilepsia|October 1, 1996
Postictal language dysfunction in patients with right or bilateral hemispheric language localizationM Privitera, C Kohler, W Cahill, et al.Lipids|May 31, 2008
Fatty Acid Profile of Sunshine Bass: II. Profile Change Differs Among Fillet Lipid ClassesJesse T Trushenski, Heidi A Lewis, Christopher C KohlerLipids|February 1, 2007
Modification of fillet composition and evidence of differential fatty acid turnover in sunshine bass Morone chrysops x M. saxatilis following change in dietary lipid sourceRyan L Lane, Jesse T Trushenski, Christopher C KohlerClinical Oral Implants Research|November 7, 1999
Regeneration of bone graft donor sitesN A Miller, J Penaud, C Kohler, et al.Journal of Pharmaceutical Policy and Practice|June 8, 2017
Promoting transparency, accountability, and access through a multi-stakeholder initiative: lessons from the medicines transparency allianceTaryn Vian, Jillian C Kohler, Gilles Forte, et al.Pageof 19